Bicara Therapeutics (BCAX) Competitors $12.06 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$12.05 -0.01 (-0.08%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. GMTX, IMVT, CPRX, KNSA, TARS, OGN, ALVO, CNTA, DNLI, and IBRXShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Gemini Therapeutics (GMTX), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Gemini Therapeutics Immunovant Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Gemini Therapeutics (NASDAQ:GMTX) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Does the media prefer GMTX or BCAX? In the previous week, Bicara Therapeutics had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Bicara Therapeutics and 1 mentions for Gemini Therapeutics. Bicara Therapeutics' average media sentiment score of 1.61 beat Gemini Therapeutics' score of 0.75 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate GMTX or BCAX? Bicara Therapeutics has a consensus target price of $32.25, suggesting a potential upside of 167.42%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is GMTX or BCAX more profitable? Bicara Therapeutics' return on equity of -21.67% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Bicara Therapeutics N/A -21.67%-20.89% Do insiders and institutionals hold more shares of GMTX or BCAX? 75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, GMTX or BCAX? Gemini Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-60.19Bicara TherapeuticsN/AN/A-$68M-$3.17-3.80 SummaryBicara Therapeutics beats Gemini Therapeutics on 11 of the 13 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$658.03M$3.12B$5.77B$9.92BDividend YieldN/A2.29%6.71%4.51%P/E Ratio-3.807.5556.5522.02Price / SalesN/A466.49534.30112.03Price / CashN/A44.9736.9659.01Price / Book1.339.8611.446.09Net Income-$68M-$53.47M$3.28B$266.14M7 Day Performance1.01%2.89%0.84%0.28%1 Month Performance6.16%8.62%7.15%4.14%1 Year PerformanceN/A13.69%59.66%23.93% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.8995 of 5 stars$12.06flat$32.25+167.4%N/A$658.03MN/A-3.8032Positive NewsGMTXGemini TherapeuticsN/A$59.650.0%N/A+24.1%$2.58BN/A-59.6530IMVTImmunovant2.8537 of 5 stars$14.69-0.9%$35.20+139.6%-47.5%$2.56BN/A-5.15120News CoveragePositive NewsAnalyst ForecastCPRXCatalyst Pharmaceuticals4.9184 of 5 stars$20.59+1.0%$33.20+61.2%-0.6%$2.52B$491.73M12.4880Insider TradeKNSAKiniksa Pharmaceuticals International3.5571 of 5 stars$33.490.0%$41.17+22.9%+38.0%$2.48B$423.24M837.46220News CoveragePositive NewsInsider TradeTARSTarsus Pharmaceuticals2.1164 of 5 stars$58.58+0.7%$66.67+13.8%+97.8%$2.47B$182.95M-25.1450News CoveragePositive NewsOGNOrganon & Co.4.7871 of 5 stars$9.40+2.3%$18.00+91.6%-56.5%$2.45B$6.40B3.494,000News CoveragePositive NewsALVOAlvotech2.7238 of 5 stars$8.07+0.2%$14.00+73.5%-29.2%$2.43B$491.98M35.091,032Short Interest ↑CNTACentessa Pharmaceuticals3.3285 of 5 stars$16.79+1.4%$31.50+87.6%+7.9%$2.25B$6.85M-9.38200Trending NewsAnalyst ForecastAnalyst RevisionDNLIDenali Therapeutics4.3451 of 5 stars$15.27-2.4%$33.62+120.1%-41.2%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.9252 of 5 stars$2.34+0.4%$10.75+359.4%-35.4%$2.21B$14.74M-4.87590 Related Companies and Tools Related Companies GMTX Competitors IMVT Competitors CPRX Competitors KNSA Competitors TARS Competitors OGN Competitors ALVO Competitors CNTA Competitors DNLI Competitors IBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAX Stock Alerts